Youjia Bio Recognized as Hangzhou Expert Workstation, Accelerating Innovation in Nucleic Acid Therapeutics
YOUJIA BIO
Nucleic Acid Drug Developer
On December 2, Hangzhou officially announced the 2024 recognition results of academicians and expert workstations. According to the requirements of the document "Measures for the Administration of Hangzhou Academician and Expert Workstations (2022 Revised Edition)," after rigorous preliminary review and expert evaluation procedures, Youjia (Hangzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "YOUJIA BIO") was successfully recognized as a "Hangzhou Expert Workstation," marking a new phase in the company’s technological research and development and talent cooperation.
The Academician and Expert Workstation in Hangzhou serves as a crucial platform for promoting high-level scientific and technological talent to serve local economic development. It is an important means of gathering high-end intellectual resources and facilitating the transformation of scientific and technological achievements.By building workstations, enterprises can introduce top expert teams from both within and outside China to carry out research on key technical issues in the industry, helping companies achieve technological innovation and transformation.
The approval of the "Hangzhou Expert Workstation" is a high recognition of the company's technological innovation and industrialization capabilities in the biopharmaceutical field, and also injects new momentum into the company’s future development.
Youjia (Hangzhou) Biomedical Technology Co., Ltd. (referred to as "YOUJIA BIO")YOUJIA BIO, founded in 2019 by returned postdoctoral fellows and senior industry experts, is a leader in the development of innovative nucleic acid technologies in China. Located in the Xiaoshan Economic and Technological Development Zone in Hangzhou, the company has 40 employees and a nearly 1500㎡ R&D laboratory. Committed to the vision of ensuring that diseases have effective treatments, YOUJIA BIO strives to provide innovative therapeutic solutions tailored to meet clinical needs.
YOUJIA BIO has established the SEQUAD nucleic acid drug full-process development platform, which can rapidly advance the development of nucleic acid drugs and the industrialization of nucleic acid technology products.YOUJIA BIO is a 5213 Talent Project in Xiaoshan District, and has been approved as a Hangzhou-level R&D center, as well as a Zhejiang Province "Specialized, Precise, Unique, and Innovative" Small and Medium-sized Enterprise.